H2 Global Group Holds International Patent for Alzheimer’s Therapy Using Molecular Hydrogen
Ostrava-based company H2 Global Group has secured an international patent for the treatment and mitigation of Alzheimer’s disease through a groundbreaking approach combining hydrogen inhalation devices, hydrogen-rich water, and targeted nutritional supplements. Now, the company is integrating this innovation into a new model of personalised healthcare—with a focus on prevention.
Scientists warn that the number of Alzheimer’s cases is rising sharply, and individuals with close family members affected by the disease are up to four times more likely to develop it themselves.
A Czech Breakthrough with Global Potential
Alzheimer’s does not only affect the elderly—changes in the brain can begin as early as age 40, eventually leading to symptoms associated with various types of dementia. A ray of hope for millions around the world may, however, be emerging from the Czech Republic.
H2 Global Group’s patent—developed in collaboration with Japanese researchers—includes a unique combination of molecular hydrogen inhalation via custom-designed generators, drinking hydrogen-rich water, and targeted supplementation. The company is now planning to introduce a digital tool that can help identify individuals with a genetic predisposition, enabling early intervention and shifting the paradigm from treatment to prevention. This aligns with H2 Global Group’s long-term focus on the development of bioactive nutrients for targeted health outcomes.
“Regular hydrogen inhalation using our H2 Vibe devices can not only alleviate symptoms in those already affected but may also prevent onset—if started early enough,” Photo credit: H2 Global Group
From Scientific Discovery to Scalable Innovation
H2 Global Group is committed to bridging the gap between research and real-world impact.
“We are applying our patents in several ongoing projects, which are often demanding in terms of time, resources, and logistics,” explains CEO Viktória Procházková. “But our core mission is not just scientific exploration—we aim to bring innovations to market swiftly, creating immediate value for both existing and new investors. We are soon launching a new two-phase brain nutrient designed to protect and regenerate the brain. Our goal is to engage at-risk individuals early and offer them effective strategies for maintaining cognitive health.”
Renowned Japanese scientist Professor Shigeo Ohta, a global authority on molecular hydrogen and long-term research partner of H2 Global Group, adds:
“We’ve identified oxidative stress and mitochondrial dysfunction as key contributors to Alzheimer’s. Hydrogen reduces inflammation, supports cognitive function, and plays a vital role in neuron protection and disease management.”
“Early detection, risk mitigation, and prevention must become part of our daily lives if we want to maintain a high quality of life without cognitive decline,” says Viktória Procházková.
Alzheimer’s: A Gateway to Innovation
Alzheimer’s affects over 55 million people worldwide, including more than 150,000 in the Czech Republic. Without intervention, these figures are expected to double by 2050.
Because brain damage may begin decades before symptoms appear, early prevention is critical. Regular hydrogen supplementation and a personalised health approach could significantly slow—or even prevent—the onset of disease.
A Future-Focused Investment Opportunity
H2 Global Group’s patented hydrogen-based therapy represents not only a breakthrough in healthcare—but also a compelling investment opportunity in the future of medicine.
“Hydrogen therapy is proving to be a revolutionary method in both prevention and treatment. Thanks to our proprietary technologies, we are now bringing these innovations from the lab into everyday medical practice,”
explains Martin Frais, Director of H2 Invest.
Combining cutting-edge science with a clear market strategy, the company is creating opportunities for investors seeking stable, forward-looking returns in the MedTech and HealthTech sectors—fields with rapidly growing importance and strong social impact.
“Hydrogen-based technologies have the potential to fundamentally transform how we approach treatment and regeneration. Demand is rising among physicians, researchers, and patients alike. This is a unique moment to participate in innovations that are redefining modern medicine. H2 Group is building a high-growth sector with global relevance and long-term investment potential,”
concludes Frais.
